March 7, 2018 / 12:13 PM / 2 months ago

BRIEF-Aptose Biosciences Announces License Agreement for Dual BET/Kinase Targeting Program With OHM Oncology ‍​

March 7 (Reuters) - Aptose Biosciences Inc:

* APTOSE BIOSCIENCES INC - ‍​

* APTOSE BIOSCIENCES - ‍ AGREEMENT PROVIDES OHM ONCOLOGY RIGHTS FOR DEVELOPMENT, MANUFACTURE AND COMMERCIALIZATION OF APL-581

* APTOSE BIOSCIENCES - TO RETAIN REACQUISITION RIGHTS TO CERTAIN MOLECULES, OHM TO HAVE RIGHTS TO DEVELOP, SUBLICENSE OTHER MOLECULES.​

* APTOSE BIOSCIENCES - ‍UNDER AGREEMENT, CO TO RECEIVE NOMINAL UPFRONT CASH PAYMENT, ELIGIBLE FOR UP TO $125 MILLION ADDITIONAL PAYMENTS BASED ON MILESTONES Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below